The information contained in this announcement has been declared by the Group to constitute internal information as stipulated in the Market Abuse Regulation (EU) No. 596/2014 (to form part of national law pursuant to the European Union (Withdrawal) Act 2018). considered. Upon publication of this announcement via the Regulatory Information Service, this inside information is considered to be in the public domain.
Oxford Biomedica Appointed Ph.D. Frank Mathias as CEO
oxford, england – November 22, 2022: Oxford Biomedica plc (LSE: OXB) (“Oxford Biomedica” or the “Company”), a leading gene and cell therapy group, today announced the appointment of Dr. Frank Matthias as Chief Executive Officer ( CEO) and Board of Directors. Directors, effective March 2023.
Dr. Mathias brings world-class innovation and contract development and manufacturing experience to Oxford Biomedica. Since 2016, he has been CEO of his Rentschler Biopharma SE (“Rentschler”), and he has successfully developed this company into a world-leading full-service CDMO. Over the past six years, Dr. Matthias has achieved his 3x increase in revenue, transforming the business, increasing efficiency and increasing revenue faster than revenue. At Rentschler, he also led the acquisition and rapid integration of a new facility from Shire in Milford, near Boston, USA, and the establishment of a new gene therapy unit in Stevenage, UK. During his tenure, Rentschler was also the first of his CDMOs in Europe to support the commercial production of BioNTech’s mRNA vaccines, and also successfully transferred the commercial production process of Curevac’s mRNA vaccines.
Prior to Rentschler, he was CEO of publicly traded Medigene AG, an immuno-oncology company focused on developing T-cell-based cancer therapies. During his 30-year career, Dr. Matthias has also held senior positions at leading global pharmaceutical companies such as Amgen, Servier and Hoechst AG. In 2019 he was awarded the title of ‘EY Entrepreneur of the Year’ in Germany.
Dr. Roch Doliveux will remain as Interim CEO of Oxford Biomedica until March 2023, at which time Dr. Mathias will assume the full CEO role and Dr. Doliveux will resume the role of Non-Executive Chairman.
As an inaugural comment, Dr. Roch Doliveux, Chairman and Interim CEO of Oxford Biomedica, Said: “Meon behalf of the Board, happy Welcome Frank as CEO of Oxford Biomedica. Frank is outstanding Patient-Centric Leader When impressive experience from a Up-end Not just for CDMOs from innovative biopharmaceutical company. He has a strong track record of growing and driving performance Innovation as a core strength requirement to execute our strategy of becoming an innovative World leader in viral vectors. I know Frank will drive viral vector leadership to unlock the potential of viruses cElle and genes ttreatment for bAn eye-pharma company to save many lives.”
Incoming Chief Executive Officer Dr. Frank Matthias said:: “Oxford Biomedica world–leader of of innovative development and Manufacturing of viral vector Life-saving cell and gene therapydemonstrated by continue to expand customer base of now Over 20 programs for all vector types. I am excited about the company’s potential as it continues to gain momentum across the business. Me look forward Participating in Oxford Biomedica When work together all of staffthe Board of Directors and partner to execute strategy, delivery next phase Grow as a world class InnovativeON LED CDMOs help improvement patient’s life. ”
There are no disclosures required to be made pursuant to LR 9.6.13R.
Oxford Biomedica plc:
Roch Doliveux, Chairman and Interim CEO – Phone: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer – Phone: +44 (0)1865 783 000
Taylor Boyd, Vice President, Head of Investor Relations – Phone: +1 919 539 1234
Sophia Bolhassan, Vice President Corporate Affairs and Investor Relations – Phone: +44 (0)7394 562 425
Consilium Strategic Communication:
Phone: +44 (0)20 3709 5700 / Email: firstname.lastname@example.org
Mary-Jane Elliott / Matthew Cole / Angela Gray
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading innovative viral vector specialist focused on delivering life-changing therapies for patients.
Oxford Biomedica plc and its subsidiaries (groups) operate across major viral vector delivery systems, including those based on lentivirus, adeno-associated virus (AAV), and adenovirus, cell and gene therapy biotechnology for process development. We provide innovative solutions to technology and biopharmaceutical companies. Analytical development and manufacturing needs. Oxford Biomedica has built his LentiVector® platform, an industry-leading lentiviral vector delivery system, working with global partners on preclinical to commercial programs across a range of therapeutic areas.
Oxford Biomedica has multiple locations and is headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US subsidiary AAV manufacturing and innovation business based near Boston, USA.
For more information, please visit www.oxb.com.